文献速递传染病防控与疫情报告

2011至2016年欧洲11国及以色列的肺炎支原体感染

Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016.
PubMed 文献 · Euro Surveill · 2020-01-01

该研究于2016年5月向欧洲及以色列17国的支原体专家发放问卷,回顾性收集2011年1月至2016年4月肺炎支原体阳性样本信息,共12国提供95,666份阳性样本数据。研究识别出2011/12、2014/15和2015/16三次流行,发现流行年份国家纬度与流行开始日历周存在关联,并注意到大环内酯类耐药监测缺乏。

要点

  • 2011至2016年间识别出三次肺炎支原体流行:2011/12、2014/15和2015/16。
  • 阳性样本年龄分布呈现三种模式,检测方法与实践存在差异。
  • 仅两家实验室自2013年起启动常规大环内酯类耐药检测,耐药监测缺乏。

核心结论

  • 观察到肺炎支原体流行与国家纬度之间存在关联。
  • 阳性病例年龄分布、所用检测方法及实践存在差异。
  • 注意到大环内酯类耐药监测缺乏。

研究设计与样本

  • 2016年5月向欧洲及以色列17国的ESCMID支原体与衣原体感染研究组国家或区域负责专家发放问卷。
  • 回顾性收集2011年1月至2016年4月肺炎支原体阳性样本信息。
  • 采用移动流行法(Moving Epidemic Method)确定五个研究时段的流行期及国家纬度效应。
  • 12国代表提供肺炎支原体感染数据,共95,666份阳性样本。

主要发现

  • 2011至2016年间识别出三次流行:2011/12、2014/15和2015/16。
  • 肺炎支原体阳性样本的患者年龄分布呈现三种模式。
  • 流行年份中,观察到国家纬度与流行期开始的日历周之间存在关联。
  • 两家实验室自2013年起启动常规大环内酯类耐药检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundMycoplasma pneumoniae is a leading cause of community-acquired pneumonia, with large epidemics previously described to occur every 4 to 7 years.AimTo better understand the diagnostic methods used to detect M. pneumoniae; to better understand M. pneumoniae testing and surveillance in use; to identify epidemics; to determine detection number per age group, age demographics for positive detections, concurrence of epidemics and annual peaks across geographical areas; and to determine the effect of geographical location on the timing of epidemics.MethodsA questionnaire was sent in May 2016 to Mycoplasma experts with national or regional responsibility within the ESCMID Study Group for Mycoplasma and Chlamydia Infections in 17 countries across Europe and Israel, retrospectively requesting details on M. pneumoniae-positive samples from January 2011 to April 2016. The Moving Epidemic Method was used to determine epidemic periods and effect of country latitude across the countries for the five periods under investigation.ResultsRepresentatives from 12 countries provided data on M. pneumoniae infections, accounting for 95,666 positive samples. Two laboratories initiated routine macrolide resistance testing since 2013. Between 2011 and 2016, three epidemics were identified: 2011/12, 2014/15 and 2015/16. The distribution of patient ages for M. pneumoniae-positive samples showed three patterns. During epidemic years, an association between country latitude and calendar week when epidemic periods began was noted.ConclusionsAn association between epidemics and latitude was observed. Differences were noted in the age distribution of positive cases and detection methods used and practice. A lack of macrolide resistance monitoring was noted.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Beeton ML, Zhang XS, Uldum SA, et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill. 2020. PMID: 31964459. doi:10.2807/1560-7917.ES.2020.25.2.1900112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。